MOBERG DERMA ACTIVATES DEFERRED TAX ASSETS The Board of Moberg Derma AB (OMX: MOB) considers it as probable that future taxable profit will be available and can be utilized against unutilized tax losses. This tax receivable is reported both in the income statement and balance sheet, resulting in a positive impact first quarter 2012 by SEK 31.8 million. The Company has outstanding tax loss carryforward of 120.8 million. ”We have achieved strong sales growth for Nalox™/Emtrix® and new agreements and product launches creates opportunities for an international expansion and continued strong growth with profitability”, say Peter Wolpert, CEO and founder of Moberg Derma. About this information Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am (CET) on March 13th, 2012. For further information, please contact: Peter Wolpert, President and CEO Telephone: +46 8 522 307 00 Mobile: +46 735 71 35 E-mail: peter.wolpert@mobergderma.se Magnus Persson, IR Mobile: +46 73-355 26 01 E-mail: magnus.persson@mobergderma.se
MOBERG DERMA ACTIVATES DEFERRED TAX ASSETS
| Source: Moberg Pharma AB
Attachments
